Semantic Scholar uses AI to extract papers important to this topic.
A beneficial effect of recombinant activated factor VII (rFVIIa) in Child‐Pugh class B and C patients with cirrhosis who have… Expand Summary. Background: Hemophilic patients with factor VIII (FVIII) and FIX inhibitors suffer from frequent bleeding episodes and… Expand CONTEXT
The US Food and Drug Administration (FDA) licensed recombinant human coagulation factor VIIa (rFVIIa) on March 25, 1999… Expand BACKGROUND
Uncontrolled bleeding is a leading cause of death in trauma. Two randomized, placebo-controlled, double-blind trials… Expand BACKGROUND & AIMS
Upper gastrointestinal bleeding (UGIB) is a severe and frequent complication of cirrhosis. Recombinant… Expand BACKGROUND
Recombinant coagulation factor VIIa (FVIIa) is approved for treating hemophiliacs with inhibitors. High-dose FVIIa has… Expand Protease-activated receptor 2 (PAR2) is expressed by vascular endothelial cells and other cells in which its function and… Expand Surgical intervention failed to stop life-threatening bleeding caused by injury complicated by severe coagulopathy… Expand High‐dose recombinant factor VIIa has been successfully used as therapy for haemophiliacs with inhibitors. The mechanism by which… Expand Blood coagulation is initiated when tissue factor binds to coagulation factor Vila to give an enzymatically active complex which… Expand